SBIR-STTR Award

Improved Cleaning Technology for Reducing Risk of Transmitting Infection in Endoscopy
Award last edited on: 9/7/23

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$3,278,572
Award Phase
2
Solicitation Topic Code
NIAID
Principal Investigator
Seo Yean Sohn

Company Information

Advanced Biodevices LLC

1 Wall Street
Princeton, NJ 08540
   (609) 683-0215
   N/A
   novaflux.com
Location: Single
Congr. District: 12
County: Mercer

Phase I

Contract Number: 1R43AI132040-01
Start Date: 3/2/17    Completed: 2/28/18
Phase I year
2017
Phase I Amount
$285,503
More than 50 million procedures were performed with GI endoscopic devices in 2009. Since endoscopes cannot be sterilized, risk of infection from contaminated endoscopes can be tangible and needs to be urgently addressed. Infection at endoscopy has recently been recognized as a significant risk after two patient deaths from CRE infection transmitted by contaminated duodenoscopes at the UCLA Medical Center in 2015. Since 2013, more than 100 patients have been affected by CRE in Chicago, Seattle, Pittsburgh, and Los Angeles. These and many other outbreaks have been reported to CDC over the years. Endoscope contamination is directly linked to inadequate cleaning by current manual cleaning protocols and by automated endoscope reprocessors (AERs). Despite manual brushing of the wider suction/biopsy channels, narrower channels cannot be brushed, and can only be flushed with enzymatic cleaners. It is now recognized that existing cleaning methods are deficient, and this is further magnified by the difficulty of removing biofilm from endoscope internal channels. To overcome the above limitations, we have developed a highly effective technology based on the flow of special nano- and microfibers through the endoscope internal channels, which results in the unparalleled removal of organic soil, bioburden and, most importantly, biofilm. During flow, floc fibers make contact with a channel surface and generate a high hydrodynamic force which, at a close distance (<100 nm), is capable of removing contaminants, including biofilm. High-level cleaning and removal of multispecies biofilm have been demonstrated in our Preliminary Studies, including in narrow 1.6 mm air/water channels that cannot be currently brushed. The technology can be envisioned as cleaning the surface of channels at nanometer or molecular levels, and can be termed “nano-brushing.” The proposed technology is based on rigorous and rational formulation of flow of suspensions and can be properly modeled as described in the proposal. This Phase I SBIR includes three Specific Aims to: i) Define MFC formulations and process parameters in simulated experiments; ii) Optimize process parameters to remove biofilm from endoscope internal channels; and iii) Adapt, refine and optimize the cleaning and rinsing processes in actual endoscopes.

Public Health Relevance Statement:
8. Project Narrative This is a tangible Phase I SBIR designed to develop a novel technology for cleaning endoscope channels of all diameters, including the narrow air/water channels (1.2 mm ID) that cannot be brushed by current manual cleaning methods. The technology is based on flowing nano- or microfibrillated cellulose (or equivalent) suspensions/gels (MFC) in the channels for 2 to 3 minutes at specified velocities, followed by water rinsing. During flow, fibers of MFC flocs make contact with the endoscope channel wall and generate a high hydrodynamic force in the contact zone sufficient to remove organic soils, bioburden and biofilm. Fiber-wall contact occurs at high frequency, and it has been estimated that a single floc makes about 104 contacts from the time of entering to that of exiting 1- meter channels. As there are billions of MFC flocs in the suspension, and there are hundreds of fibers/floc, the total contact area during flow can be estimated. We derived an equation to estimate the number of channel surface treatments that can be achieved during the 2-3 minute flow (Treatment Number, TN) and have found that this (TN) may be about 103. Accordingly, we are able to treat the channel surface about 1000 times during the MFC flow. As the generated hydrodynamic force is high (about 20-30 times that of bulk shear), the shear stress created is sufficient to provide nearly perfect removal of contaminants, including biofilm. In our Preliminary Studies, we have demonstrated the high-level cleaning that can be achieved with the new MFC technology. MFC flow in narrow channels can be made with the aid of a simple pumping system; hence, it is easy to apply and to readily implement the technology in the field. Since suspension flow can be described by physical modeling, the technology can be developed on the basis of rational science. The utility and need for this technology are high in light of new findings that biofilm contamination of channels may have been an important factor in the recent CRE outbreaks that resulted in patient deaths at the UCLA Medical Center in 2015. We believe that this new technology will significantly improve endoscope cleaning and decrease risk of infection such as CRE. This Phase I study is planned to collect essential data necessary to complete the development of the technology in Phase II. We have assembled a highly experienced team to execute the tasks of this Phase I study. Members of the team have an excellent track record in developing medical devices that were cleared by FDA, as detailed in the Biosketches. We have included Dr. Paul Stoodley as a consultant to assist in biofilm studies during the project. Our facilities are more than sufficient to execute all of the Aims in-house, except for the SEM investigation which will be outsourced as needed. Considering that there are more than 50 million GI endoscopic procedures performed annually in the United States, the MFC technology has significant commercial potential because of its superior performance in cleaning endoscope channels compared to existing technologies. The Phase I study includes three (3) Aims to: i) Define MFC formulations and process parameters in simulated experiments; ii) Optimize process parameters to remove biofilm from endoscope internal channels; and iii) Adapt, refine and optimize the cleaning and rinsing processes in actual endoscopes.

Project Terms:
abstracting; Address; Affect; Air; Area; Australia; base; Biopsy; Caliber; Cellulose; Centers for Disease Control and Prevention (U.S.); Cessation of life; Chicago; Complex; Congresses; Data; design; Development; Devices; Disease Outbreaks; Drops; Duodenoscopes; Endoscopes; Endoscopic Retrograde Cholangiopancreatography; Endoscopy; Equation; Europe; Excision; experience; experimental study; Fiber; Flushing; Formulation; Foundations; Frequencies; Future; Gel; Growth; Hospitals; Housing; hydrodynamic flow; improved; Infection; Investigation; Irrigation; Lead; Left; Life; Light; Link; Los Angeles; Manuals; Manufacturer Name; Medical center; Medical Device; member; meter; Methods; Microbial Biofilms; Modeling; Molecular; nano; nanofiber; nanometer; new technology; news; Organism; Patients; Performance; Phase; phase 1 study; physical model; pressure; Procedures; Process; Protocols documentation; Pump; Recommendation; Regulation; Reporting; Risk; Science; shear stress; Small Business Innovation Research Grant; Soil; Specific qualifier value; Suction; Surface; Suspensions; System; Technology; technology development; Time; Travel; United States; Water; water chan

Phase II

Contract Number: 2R44AI132040-02
Start Date: 3/2/17    Completed: 7/31/21
Phase II year
2018
(last award dollars: 2020)
Phase II Amount
$2,993,069

Outbreaks of infection caused by contaminated endoscopes are a serious public health problem that has even resulted in patient deaths. Currently, because of the narrowness of the channels and complexity of the endoscope, there simply is no reliable way of achieving this. The existing cleaning protocols also are highly dependent on operator technique. Accordingly, this is an urgent public health problem. The work in Phase I has demonstrated that cleaning can be achieved by flowing, through endoscope channels, a new material based on safe nanofibers in an aqueous composition. The new material forms a highly?entangled network. The Phase I study included testing with soils containing live bacteria, and various types of biofilm. This work included testing many compositions, including variations of both the entangled material and the aqueous composition. The work included investigating the characteristics and manufacturing processes of this new material, formulating the aqueous composition, and determining the operating parameters for the cleaning process, including adaptations for different diameters of channels. Several new methods were developed and used for recovering, sampling, detecting and quantitating bacteria and organic materials. It has been shown that the flowing composition can effectively scrape and remove biofilm, even build?up biofilm, from the walls of the channels of all endoscope?relevant sizes, even in channels that are too narrow to brush. It has also been shown that this composition can be fully rinsed from the channels and that it does not clog the endoscope. The results demonstrated that channels that have been cleaned by the new technology are essentially indistinguishable from tubing that has never been exposed to bacteria or biofilm. Such effective cleaning has never before been achieved in endoscope reprocessing. Phase II is intended to move this NanoClean technology from these current laboratory results to a point that is close to commercialization. Phase II will involve developing a robust clinician?usable system for delivering the cleaning composition to endoscopes. It will involve scaling up procedures for manufacturing the new nanofiber?based material and the overall cleaning composition because it will be necessary to manufacture these in significantly large batch sizes in a GMP environment. Packaging of the composition for use will also be investigated. Stability and shelf life will be tested with a target value of one year. Phase II will involve simulated testing in actual endoscopes to compare NanoClean against current manufacturer?prescribed cleaning methods for three types of endoscopes (gastroscopes, colonoscopes and duodenoscopes) from the three major manufacturers (Olympus, Pentax and Fujinon). Phase II will also include assessing the NanoClean technology with patient?used endoscopes in an endoscopy facility, and comparing the NanoClean to manufacturer?prescribed cleaning methods. Again, this will be done for 20 consecutive uses with patient? used endoscopes. Endoscopes that are used on patients will continue to receive currently approved reprocessing protocols in addition to the NanoClean procedures so that there will not be any need for a special review process. Finally, feedback from staff will be obtained to use in the commercialization of the product.

Public Health Relevance Statement:
8.

Project narrative:
Endoscope?caused infections, which are a serious public health hazard, occur because the internal channels of an endoscope are so long and narrow that it is difficult to remove contaminants, such as biofilm, which harbors and protects bacteria and actually helps bacteria survive traditional high?level disinfection, from them. Phase I demonstrated that flow of a safe nanofiber?based material in an aqueous composition through an endoscope channel can scrub biofilm and other contaminants to such an extent that the channel is indistinguishable from a channel that has never been exposed to bacteria or biofilm. This is an unprecedented accomplishment in the endoscope reprocessing industry. Phase II will advance this technology toward commercialization by: 1) developing and validating a delivery pump system, 2) scaling up the nanofiber?based cleaning composition and manufacturing processes, 3) testing the new technology in repeated simulated?use cycles with the most challenging three types of actual endoscopes, and 4) testing patient?used endoscopes through multiple (20) consecutive uses in a healthcare facility.

NIH Spending Category:
Bioengineering; Biomedical Imaging; Digestive Diseases; Infectious Diseases; Nanotechnology; Prevention

Project Terms:
3-Dimensional; Advocate; aqueous; Award; Bacteria; base; Caliber; carbapenem-resistant Enterobacteriaceae; Cellulose; Cessation of life; Characteristics; Colonoscopes; commercialization; comparative efficacy; Congresses; Consensus; Cross Infection; Cyclic GMP; Data; Data Set; Dental; design; Devices; Diagnostic Procedure; Disease Outbreaks; Disinfection; Documentation; Duodenoscopes; Endoscopes; Endoscopy; Environment; Excision; Exposure to; Feedback; Fiber; flexibility; Flushing; Formulation; Gastroscopes; Guidelines; Health care facility; Health Hazards; Healthcare; Human; improved; Income; Industry; Infection; Infection Control; Laboratories; Life; Manufacturer Name; manufacturing process; Medical center; Medical Technology; meetings; Methods; microbial; Microbial Biofilms; Modeling; Multi-Drug Resistance; nano; nanofiber; National Institute of Allergy and Infectious Disease; new technology; Patients; Phase; phase 1 study; prevent; Procedures; Process; Production; Protocols documentation; prototype; Public Health; Pump; quality assurance; Recording of previous events; Reporting; Residual state; Risk; Sampling; scale up; simulation; Site; Soil; Solid; Speed; Sterilization; success; Surface; System; Techniques; Technology; Technology Assessment; Technology Transfer; Testing; transmission process; Vari